Clinical Trials DEA Patients Therapy 
Veriheal
JUNE 29, 2021
In the last 100 years, many of the plant therapies that were embraced in history were outlawed by governments around the world and replaced by lab-made synthetic drugs we label medicine. A Push by Patients. The lawsuit came after the DEA denied their application to utilize a synthetic form of psilocybin under the RTT laws.
Cannabis Law Report
OCTOBER 4, 2021
Advanced Illness , Oregon Psilocybin Advisory Board , Oregon Psilocybin Services Act , Psilocybin , Psilocybin Therapy , Psychedelics , Right To Try. One of the known beneficial uses of psilocybin is as a palliative care tool for patients with advanced illness who suffer from anxiety and/or depression.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
SpeedWeed
MAY 15, 2021
A first-of-its-kind Phase 3 clinical trial has found that MDMA-assisted therapy provided meaningful relief from PTSD symptoms in nearly 90 percent of study participants. For this study, researchers recruited 90 patients suffering from severe, chronic PTSD. Image via. View original article.
Cannabis Law Report
AUGUST 18, 2022
The firm’s deep expertise in pharmaceutical sciences, FDA regulatory compliance and pharmaceutical product liability litigation and risk management enables it to address complex legal hurdles faced by stakeholders seeking to research, develop, invest in and bring-to-market psychedelic therapies. BUFFALO, N.Y. , Aug. Tweet this.
Cannabis Law Report
NOVEMBER 22, 2019
MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”. .
Cannabis Law Report
APRIL 21, 2022
The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public .
Cannabis Law Report
APRIL 8, 2022
as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. In MAPS’ 36th year, we’ll learn if our second Phase 3 study of MDMA-assisted therapy for PTSD was successful. Later that year, Doblin sued the DEA for the first time. Rick Doblin, Ph.D.,
Expert insights. Personalized for you.
55 
Let's personalize your content